Table 2. Licensed dosing for... | American Society of Hematology

Table 2.

Licensed dosing for thrombopoietin-agonists for patients with cirrhosis and platelet count <50 × 10⁹/L prior to invasive procedures

TPO-R agonist	Baseline platelet count^* ( × 10⁹/L)	Dose	Procedure date^#
Lusutrombopag	<50	3 mg once daily for 7 days	Day 9-14
Avatrombopag	<40	60 mg once daily for 5 days	Day 10-13
Avatrombopag	40-49	40 mg once daily for 5 days	Day 10-13

TPO-R agonist	Baseline platelet count^* ( × 10⁹/L)	Dose	Procedure date^#
Lusutrombopag	<50	3 mg once daily for 7 days	Day 9-14
Avatrombopag	<40	60 mg once daily for 5 days	Day 10-13
Avatrombopag	40-49	40 mg once daily for 5 days	Day 10-13

TPO-R agonist, thrombopoietin-receptor agonist.

If platelet count <30 × 10⁹/L, consider and correct other causes of thrombocytopenia.

Number of days following initiation of TPO-R agonist.